Clinical Trials Browser

Phase 1/2 × Myeloid Malignancies × Clear all

NCT06930651 2026-03-11

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Phase 1/2 Recruiting

Myeloid Malignancies

NCT06917105 2025-04-08

Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies

Phase 1/2 Not yet recruiting

Myeloid Malignancies

NCT02958397 2019-06-25

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Phase 1/2 Unknown

Myeloid Malignancies

NCT02958384 2018-01-23

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Phase 1/2 Unknown

Myeloid Malignancies